Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01838 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Daphne A Haas-Kogan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Bos…. Hauptthemen laut MEDLINE: Everolimus, Glioma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, NCI NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers. PATIENTS AND METHODS Patients, age 3-21 years, with progressive/recurrent pLGG received everolimus orally, 5 mg/m 2 once daily. Frequency of driver gene alterations was compared among independent pLGG cohorts of newly diagnosed and progressive/recurrent patients. PFS at 6 months (primary end point) and median PFS (secondary end point) were estimated for association with everolimus therapy. RESULTS Between 2012 and 2019, 65 subjects with progressive/recurrent pLGG (median age, 9.6 years; range, 3.0-19.9; 46% female) were enrolled, with a median follow-up of 57.5 months. The 6-month PFS was 67.4% (95% CI, 60.0 to 80.0) and median PFS was 11.1 months (95% CI, 7.6 to 19.8). Hypertriglyceridemia was the most common grade ≥3 adverse event. PI3K/AKT/mTOR pathway activation did not correlate with clinical outcomes (6-month PFS, active 68.4% v nonactive 63.3%; median PFS, active 11.2 months v nonactive 11.1 months; P = .80). Rare/novel KIAA1549::BRAF fusion breakpoints were most frequent in supratentorial midline pilocytic astrocytomas, in patients with progressive/recurrent disease, and correlated with poor clinical outcomes (median PFS, rare/novel KIAA1549::BRAF fusion breakpoints 6.1 months v common KIAA1549::BRAF fusion breakpoints 16.7 months; P < .05). Multivariate analysis confirmed their independent risk factor status for disease progression in PNOC001 and other, independent cohorts. Additionally, rare pathogenic germline variants in homologous recombination genes were identified in 6.8% of PNOC001 patients. CONCLUSION Everolimus is a well-tolerated therapy for progressive/recurrent pLGGs. Rare/novel KIAA1549::BRAF fusion breakpoints may define biomarkers for progressive disease and should be assessed in future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA.
- Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT.
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
- Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
- Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA.
- Department of Pediatrics, University of Washington, Seattle, WA.
ORCID-Profile: Daphne A Haas-Kogan, Mariam S Aboian, Sarah E S Leary, Mohamed S Abdelbaki, Jennifer D Elster, Adam Kraya, Matthew R Lueder, Divya Ramakrishnan, Marc von Reppert, Kevin X Liu, Jo Lynne Rokita, Adam C Resnick, David A Solomon, Joanna J Phillips, Michael Prados, Annette M Molinaro, Sebastian M Waszak, Sabine Mueller
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- NCI NIH HHS
Zitieren
APA
Haas-Kogan, D. A., Aboian, M. S., Minturn, J. E., Leary, S. E. S., Abdelbaki, M. S., Goldman, S., Elster, J. D., Kraya, A., Lueder, M. R., Ramakrishnan, D., von Reppert, M., Liu, K. X., Rokita, J. L., Resnick, A. C., Solomon, D. A., Phillips, J. J., Prados, M., Molinaro, A. M., Waszak, S. M., & Mueller, S. (2024). Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01838
Vancouver
Haas-Kogan DA, Aboian MS, Minturn JE, Leary SES, Abdelbaki MS, Goldman S, et al. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01838
BibTeX
@article{HaasKogan2024,
author = {Haas-Kogan, Daphne A and Aboian, Mariam S and Minturn, Jane E and Leary, Sarah E S and Abdelbaki, Mohamed S and Goldman, Stewart and Elster, Jennifer D and Kraya, Adam and Lueder, Matthew R and Ramakrishnan, Divya and von Reppert, Marc and Liu, Kevin X and Rokita, Jo Lynne and Resnick, Adam C and Solomon, David A and Phillips, Joanna J and Prados, Michael and Molinaro, Annette M and Waszak, Sebastian M and Mueller, Sabine},
title = {Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01838}
}
EUVIMED